Oric Pharmaceuticals Inc. Key Takeaways

Goldman Sachs provides key takeaways from Oric Pharmaceuticals' presentation at the 47th Annual Global Healthcare Conference. The report highlights progress on rinzimetostat and enozertinib programs and maintains a Buy rating.

Key Takeaways

• 1.Management views the FULC poceradir PRC2 discontinuation as sickle-cell-specific with limited ORIC read-through.
• 2.ORIC is prioritizing a firmer durability read over a faster timeline for the post-ARPI population data update.
• 3.The company has confirmed its Ph3 trial design for rinzimetostat after an end of Phase 1 FDA meeting.

Table of Contents

• Key Takeaways
• Valuation/Risks
• Disclosure Appendix

Document Preview

Page 1 of 1

Subscribe for full accessStart Free Trial